TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02290067

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood glucose monitoring system (Omnitest 5)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood glucose monitoring system (Omnitest 5D)
Study: NCT00280319

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: interpersonal psychotherapy for groups
Description: psychotherapy
Study: NCT00378716

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin calcium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tegafur

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: uracil
Study: NCT02384252

Intervention type: OTHER
Intervention: functional tissu atrial analysis

Intervention type: OTHER
Intervention: functional tissu atrial analysis
Study: NCT01956019

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI scanning
Study: NCT04263428

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Irregular sleep
Description: Experimental-induced sleep variability
Study: NCT03647046

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Customized Scleral Lens
Description: A wavefront customized scleral lens will be made for each subject and tested against a non-customized lens.
Study: NCT02254018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bivatuzumab mertansine
Study: NCT03508687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300mg Gemcabene
Description: 300mg Gemcabene

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 600mg Gemcabene
Description: 600mg Gemcabene
Study: NCT03966846

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kefir

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Milk
Study: NCT03861663

Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasound
Description: Eligible subjects will be positioned for their ultrasound exam, which will take a similar amount of time and be performed in a similar manner as standard of care ultrasound exams at the site. The type and duration of ultrasound exam will be based on the subject's clinical condition.
Study: NCT04734119

Intervention type: OTHER
Intervention: Pre operative evaluation and anesthesia administration by the same anesthesiologist
Description: Pre operative evaluation and anesthesia administration by the same anesthesiologist (instead of two different anesthesiologists, as routinely performed in our medical center)
Study: NCT01460901

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GD2 CAR modified Tri-virus specific cytotoxic t-cells
Description: This is a feasibility study to assess safety of an infusion of chimeric-antigen receptor gene modified allogeneic virus specific T lymphocytes after reduced intensity allogeneic stem cell transplant. Three patients were treated and safety was evaluated. Patients received a single infusion of 2x10e6/m2 donor derived, GD2 CAR modified, tri-virus specific CTL performed 30-120 days after allogeneic stem cell transplantation
Study: NCT02784782

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthesis

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No orthesis
Study: NCT02710513

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-glucans
Description: 2 months Mediterranean Diet-based free diet (run-in) + 2 months Mediterranean Diet-based free diet with a daily supplementation of 100 g of beta-glucans pasta (intervention). Medical visits, dietary counselling with food frequency questionnaires administration, blood, urine and feces collection were performed before (T0) and after (T2) the two months of beta-glucans intervention.
Study: NCT02867657

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Five days MBSR curriculum with meditation and yoga
Study: NCT00280319

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: creative play therapy
Description: consisted of play activities
Study: NCT03377244

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HBHS
Description: Faith based diabetes curriculum that teaches participants to connect faith and health plus church-level policy changes that encourages participants to engage in healthy behaviors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HBHS Policy
Description: Church-level policy changes that encourages participants to engage in healthy behaviors.
Study: NCT02867657

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness
Description: Five days MBSR curriculum with meditation and yoga
Study: NCT04079127

Intervention type: DEVICE
Intervention: Patients who met the inclusion/exclusion criteria to receive the Avenir Müller stem.
Description: Consecutive cohort of patients enrolled at every site who received the Avenir Müller stem.
Study: NCT02357342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: intravitreal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care intravitreal injections of anti-VEGF
Description: intravitreal injections of anti-VEGF
Study: NCT03377244

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: WORD DPP
Description: Faith based diabetes curriculum that teaches participants to connect faith and health.
Study: NCT02467946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adcetris-Levact
Description: Association of Adcetris (1.2 mg/kg intravenously every 3 weeks) with Levact (90 mg/m2/day intravenously for 2 days every 3 weeks) during at least 6 cycles.
Study: NCT00174785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dronedarone (SR33589)
Description: oral administration (tablets)
Study: NCT01853410

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: gekoTM
Study: NCT00043537

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Effectiveness Therapy for Children (SET-C)
Study: NCT00174785

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration (tablets)
Study: NCT03698188

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injectable platelet-rich fibrin
Description: A blood sample will be drawn from the patient, centrifuged at 700 rpm for 3 minutes and the upper yellow fluid will be collected by a plastic syringe, avoiding the inclusion of the red blood cells underneath, and will be introduced within the root canal.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Platelet-rich plasma
Description: A blood sample will be drawn from the patient, centrifuged at 3000 rpm for 10 minutes and the upper yellow fluid will be collected by a plastic syringe, avoiding the inclusion of the red blood cells underneath, and will be introduced within the root canal.
Study: NCT03619291

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: walking on a treadmill at moderate intensity, total duration 15 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity functional training
Description: functional exercises in circuit format at 20/10 s (work/rest) intervals, total duration 15 minutes

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: control
Description: physical inactivity, reading sports science literature, total duration 15 minutes
Study: NCT01724112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2940094
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT00043537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pill Placebo
Study: NCT00303875

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral dietary and exercise intervention
Study: NCT01857648

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity counseling
Description: Home visits including physical activity promotion by the trained Community Health Workers.
Study: NCT03608904

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music listening
Description: Familiar and unfamiliar music selections, listening duration of approximately 15 minutes, three times daily, 90-day listening duration.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Spoken word (language) listening
Description: Familiar and unfamiliar spoken word (language) selections, listening duration of approximately 15 minutes, three times daily, 90-day listening duration.
Study: NCT01656317

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early multidisciplinary rehabilitation
Description: Multidisciplinary rehabilitation consist of individualized stimulation and mobilisation.~The multidisciplinary team consists of a physician, a nurse, a physiotherapist, an occupational therapist and a clinical neuropsychologist.
Study: NCT02867449

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metacognitive Therapy
Description: Metacognitive Therapy for OCD according to Wells (1997)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure and Response Prevention
Description: Exposure and Response Prevention for OCD according to Kozak \& Foa (1997)
Study: NCT04084626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD1 antibody
Description: 2mg/kg ivgtt on day 1(age\<18 years); 200mg ivgtt on day 1(age \>=18 years).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: 5mg orally once a day（age\<18years) ,day 1-14; 10mg orally once a day(age\>=18years), day 1-14.
Study: NCT02490917

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACT™ device
Description: Implantation of the Adjustable Continence Therapy device ACT®

Intervention type: DEVICE
Group type: OTHER
Intervention: AMS 800 ™ device
Description: Implantation of the artificial urinary sphincter AMS 800 ™
Study: NCT01885858

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Indigenous profile
Description: Clinics receive simulated patients (SPs) enacting the indigenous profile, and interpreting a standardized script with a biographical and clinical background. The indigenous SP wears a lliclla (a traditional woven cloth that covers the back and shoulders), long braids, a woven cardigan and loose pants; she uses no make-up and, her patterns of speech are slower and her posture and movement more rigid than the mestizo SP. The script indicates that SPs do not want to have any more children and that her choice of method is the pill.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Indigenous profile
Description: Clinics receive simulated patients (SPs) enacting the indigenous profile, and interpreting a standardized script with a biographical and clinical background. The indigenous SP wears a lliclla (a traditional woven cloth that covers the back and shoulders), long braids, a woven cardigan and loose pants; she uses no make-up and, her patterns of speech are slower and her posture and movement more rigid than the mestizo SP. The script indicates that SPs do not want to have any more children and that her choice of method is the pill.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mestizo profile
Description: Clinics receive simulated patients (SPs) enacting the mestizo profile, and interpreting a standardized script with a biographical and clinical background. The mestizo SP does not wear a lliclla (a traditional woven cloth that covers the back and shoulders) or long braids, but a pony tail or loose hair; she wears make-up and, a vest made of polar fleece, tight pants and culturally salient accessories; her patterns of speech are faster and her posture and movement less rigid than the indigenous SP. The script indicates that SPs do not want to have any more children and that her choice of method is the pill.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mestizo profile
Description: Clinics receive simulated patients (SPs) enacting the mestizo profile, and interpreting a standardized script with a biographical and clinical background. The mestizo SP does not wear a lliclla (a traditional woven cloth that covers the back and shoulders) or long braids, but a pony tail or loose hair; she wears make-up and, a vest made of polar fleece, tight pants and culturally salient accessories; her patterns of speech are faster and her posture and movement less rigid than the indigenous SP. The script indicates that SPs do not want to have any more children and that her choice of method is the pill.
Study: NCT02293902

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sarilumab SAR153191 (REGN88)
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sarilumab SAR153191 (REGN88)
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous
Study: NCT02493764

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tazobactam
Description: Tazobactam 500 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
Study: NCT01868711

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavior Therapy
Study: NCT02293902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab SAR153191 (REGN88)
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab SAR153191 (REGN88)
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for sarilumab)
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for sarilumab)
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Dispensed according to local practice.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Dispensed according to local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Dispensed according to local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Dispensed according to local practice.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folic acid
Description: Dispensed according to local practice.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folic acid
Description: Dispensed according to local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic acid
Description: Dispensed according to local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic acid
Description: Dispensed according to local practice.
Study: NCT01868711

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Behavior Therapy
Study: NCT02493764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: Linezolid 600 mg administered open-label by IV every 12 hours for up to 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: Linezolid 600 mg administered open-label by IV every 12 hours for up to 14 days
Study: NCT03218917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brensocatib 10 mg
Description: Administered once per day for 24 weeks
Study: NCT00918086

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D pill
Description: Oral tablet taken for 16 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An inactive pill that looks and tastes like the Vitamin D pill
Study: NCT01544803

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eScreen
Description: The eScreen brief Internet intervention for problematic alcohol and drug use offers self-screening, in-depth self-reporting, personalized feedback and treatment recommendations as well as an electronic diary. Progress over time is shown in diagrams detailing consumption levels.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alkoholhjalpen
Description: An extensive Internet intervention for problematic alcohol use, Alkoholhjalpen,provides CBT- and MI-based psycho-education with a solution-oriented focus, electronic diary and moderated chat-forum.
Study: NCT03218917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brensocatib 25 mg
Description: Administered once per day for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered once per day for 24 weeks
Study: NCT03764111

Intervention type: DEVICE
Intervention: Large Mobile Ultrasound System
Description: 30 spine images, 15 Transverse abdominis muscle and 30 Obstetric images (i.e placenta, uterine blood flow, etc) images will be obtained using the large mobile ultrasound system.

Intervention type: DEVICE
Intervention: Handheld Ultrasound Machine
Description: 30 spine images, 15 Transverse abdominis muscle and 30 Obstetric images (i.e placenta, uterine blood flow, etc) images will be obtained using the handheld device.
Study: NCT04044963

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and Prehabilitation
Description: All participants who are allocated to the exercise group will be asked to complete 4-5 days per week of mixed modality exercise incorporating aerobic, resistance, and flexibility training. The aerobic component can include any modality the patient is capable of doing, including walking, swimming or biking. By the end of the prehabilitation period the target will be 30 minutes of aerobic exercise three times a week at an intensity of 3-5 RPE. The resistance component will include 5-6 exercises using body weight and resistance bands. The target will be 12 repetitions and 3 sets, two times a week. The flexibility component will include 5 exercises that can be completed at the end of each session.~Participants will self-report their participation in the prehabilitation program based on an electronic survey.
Study: NCT04402710

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-compassion
Description: Six week behavioural change program plus a self-compassion intervention aimed to increase physical activity among individuals with prediabetes

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Six week behavioural change program aimed to increase physical activity plus information on general health topics.
Study: NCT01977222

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THRESHOLD(TM) INSPIRATORY MUSCLE TRAINER
Description: Subjects will be provided with noseclips and a threshold impedance device set to 40% of their measured maximal inspiratory pressure and will be trained on using the device. Specifically, subjects will be instructed to breathe through the inspiratory muscle training device while wearing noseclips at a rate of 12 to 16 breaths per minute for 30 minutes a day, 5 days a week for 12 consecutive weeks. Each subject will be provided a customized schedule for increasing resistance by 2 cm H2O every 2 weeks to a maximum resistance of 41 cm H2O.
Study: NCT01486303

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Facial Cosmetic Acupuncture
Description: Patients received five treatment sessions during 3 weeks. Facial cosmetic acupuncture was applied at muscles and acupoints on the face, head and neck
Study: NCT02042339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Description: The treatment will be applied in a large walk-in drive-in hyperbaric chamber. Depending on their general condition, the patients will sit in comfortable chairs or remain in their own wheelchair or bed in relaxed position. They will be accompanied by a medical attendant or by a hyperbaric physician if necessary due to their general condition. Oxygen 100% will be distributed over a tight fitting oxygen-mask connected to the overboard-dumping system. The treatment will be administered according to the so-called problem-wound schedule once a day for six consecutive weeks. On weekends and on public holidays the patients will be off therapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hyperbaric oxygen
Description: The treatment will be applied in a large walk-in drive-in hyperbaric chamber. Depending on their general condition, the patients will sit in comfortable chairs or remain in their own wheelchair or bed in relaxed position. They will be accompanied by a medical attendant or by a hyperbaric physician if necessary due to their general condition. Oxygen 100% will be distributed over a tight fitting oxygen-mask connected to the overboard-dumping system. The treatment will be administered according to the so-called problem-wound schedule once a day for six consecutive weeks. On weekends and on public holidays the patients will be off therapy.
Study: NCT02742441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 122-0551 Foam
Description: Topical Foam containing active drug
Study: NCT02300896

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group-based exercise training during hospitalization
Description: Exercise training. Individual program training 5 days a week during hospitalization
Study: NCT02723136

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone Application
Description: Smartphone application developed by internists and engineers. Will be made available on iOS(R) and Android(R) operating systems.
Study: NCT02943512

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discharge day of procedure
Description: Subjects will be discharged the day of the procedure if safe
Study: NCT00615251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-2011
Description: Progesterone vaginal ring for approximately 10 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crinone 8%
Description: progesterone vaginal gel for approximately 10 weeks
Study: NCT00379262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Dose:1000 mg/m2, BD, Day 1-Day 14 Interval: 21 days Cycles: 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Dose:1000 mg/m2, BD, Day 1-Day 14 Interval: 21 days Cycles: 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy using PF (5-Fluorouracil )
Description: Cisplatin 80 mg/m2 IV + 5-Fluorouracil 1000 mg/m2/day IV infusion for 96 hr every 28 days for 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy using PF (5-Fluorouracil )
Description: Cisplatin 80 mg/m2 IV + 5-Fluorouracil 1000 mg/m2/day IV infusion for 96 hr every 28 days for 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy using PF (5-Fluorouracil)
Description: Cisplatin 100 mg/m2 IV + 5-Fluorouracil 1000 mg/m2/day IV infusion for 120 hr every 21 days for 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy using PF (5-Fluorouracil)
Description: Cisplatin 100 mg/m2 IV + 5-Fluorouracil 1000 mg/m2/day IV infusion for 120 hr every 21 days for 3 cycles